We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+10.78%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.58B
AUM Growth
+$312M
Cap. Flow
+$159M
Cap. Flow %
6.16%
Top 10 Hldgs %
33.71%
Holding
96
New
19
Increased
23
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$59M
2
SYK icon
Stryker
SYK
+$39M
3
ALKS icon
Alkermes
ALKS
+$34.9M
4
ICLR icon
Icon
ICLR
+$31.7M
5
ABBV icon
AbbVie
ABBV
+$31.6M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$38.8M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$35.7M
3
AVTR icon
Avantor
AVTR
+$28.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$21.7M
5
ICUI icon
ICU Medical
ICUI
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOH icon
26
Molina Healthcare
MOH
$10.2B
$43.3M 1.68%
143,779
– –
DHR icon
27
Danaher
DHR
$138B
$42.2M 1.64%
198,178
– –
THC icon
28
Tenet Healthcare
THC
$21.8B
$41.6M 1.62%
511,394
+154,453
+43% +$11M
SYK icon
29
Stryker
SYK
$133B
$41.2M 1.6%
+135,022
New +$39M
ARGX icon
30
argenx
ARGX
$54.6B
$40.8M 1.58%
104,732
– –
BDX icon
31
Becton Dickinson
BDX
$45.6B
$40.6M 1.58%
153,955
+2,942
+2% +$747K
ALKS icon
32
Alkermes
ALKS
$8.39B
$36M 1.4%
+1,151,384
New +$34.9M
AXSM icon
33
Axsome Therapeutics
AXSM
$12.1B
$35.6M 1.38%
495,582
-110,499
-18% -$8.15M
DVAX
34
DELISTED
Dynavax Technologies
DVAX
$34.9M 1.36%
2,704,917
-1,100,453
-29% -$12.5M
ELV icon
35
Elevance Health
ELV
$81.6B
$33.4M 1.3%
75,122
+42,539
+131% +$19.6M
TMO icon
36
Thermo Fisher Scientific
TMO
$214B
$32.4M 1.26%
62,143
– –
ACHC icon
37
Acadia Healthcare
ACHC
$2.62B
$30.4M 1.18%
381,302
+70,367
+23% +$5.09M
BMRN icon
38
BioMarin Pharmaceuticals
BMRN
$11.7B
$30.4M 1.18%
350,298
+190,732
+120% +$17.9M
KRTX
39
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$30M 1.16%
138,209
– –
RCUS icon
40
Arcus Biosciences
RCUS
$3.55B
$28.5M 1.11%
1,405,056
-154,891
-10% -$2.95M
WAT icon
41
Waters Corp
WAT
$37.3B
$25.2M 0.98%
94,624
– –
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
$25M 0.97%
274,498
-9,771
-3% -$843K
BLUE
43
DELISTED
bluebird bio
BLUE
$24M 0.93%
364,256
+134,967
+59% +$9.87M
CRBU icon
44
Caribou Biosciences
CRBU
$150M
$23.7M 0.92%
5,570,869
+558,751
+11% +$2.51M
SRPT icon
45
Sarepta Therapeutics
SRPT
$1.64B
$19M 0.74%
+165,765
New +$21.4M
RETA
46
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$14.8M 0.57%
+145,147
New +$13.7M
BSX icon
47
Boston Scientific
BSX
$68.4B
$14.5M 0.56%
+268,397
New +$14M
AXSM icon
48
CALL
Axsome Therapeutics
AXSM
$12.1B
$14.4M 0.56%
+200,000
New +$14.8M
GBIO
49
DELISTED
Generation Bio
GBIO
$14.3M 0.55%
259,744
-5,086
-2% -$233K
DAWN
50
DELISTED
Day One Biopharmaceuticals
DAWN
$13.7M 0.53%
+1,147,140
New +$15M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
AC
AWM Capital Phoenix, Arizona $1.1B AUM 15.03% 1-Year Est. Return

PFM Health Sciences's Q2 2023 Portfolio in Review

As of Q2 2023, PFM Health Sciences held 96 positions worth $2.58B, up 14% from $2.26B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences deployed $159M of net new capital in Q2 2023, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was Biogen: 198,334 shares worth $56.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $38.8M trimmed.

  • PFM Health Sciences's largest Q2 2023 buy was Biogen: 198,334 shares worth $56.5M.
  • PFM Health Sciences added most to Icon in Q2 2023, an estimated $31.7M increase.
  • PFM Health Sciences's biggest Q2 2023 reduction was uniQure, cutting an estimated $38.8M.
  • PFM Health Sciences fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $35.7M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $2.58B portfolio in Q2 2023.
  • PFM Health Sciences opened 19 new positions and closed 13 in Q2 2023.
  • PFM Health Sciences's portfolio value rose 14% quarter-over-quarter to $2.58B.

Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.